Trading was light with 17K shares changing hands on Tuesday. Shares saw a steep decrease in trading volume of 86.80% under the normal average daily volume.
Short traders are feeling a little more bullish on shares of Prana Bio Ltd Ads S1 recently if you look at the decrease in short interest. The firm saw a fall in short interest from September 29, 2017 to October 13, 2017 of -8.14%. Short interest fell 6,575 over that timeframe. With short interest at 74,221 and short average daily volume at 12,193, the short-interest ratio is 6.0 and the percentage of shorted shares is 0.00% as of October 13.
These firms have modified their investment in PRAN. As of quarter end Bank Of America Corp /de/ had sold 166 shares trimming its position 15.1%. The value of the investment in PRAN went from $3,000 to $2,000 decreasing 33.3% since the last quarter. As of the end of the quarter Ubs Group Ag had disposed of a total of 3,198 shares trimming its stake by 89.4%. The value of the investment in Prana Bio Ltd Ads S1 decreased from $11,000 to $1,000 a change of $10,000 quarter over quarter.
As of quarter end Citadel Advisors LLC had acquired 1,933 shares growing its holdings by 16.0%. The value of the company’s investment in Prana Bio Ltd Ads S1 went from $28,000 to $39,000 a change of 39.3% for the reporting period.
The company is so far trading up from yesterday’s close of 3.19. The company’s P/E ratio is N/A and market capitalization is 29.37M. As of the latest earnings report the EPS was $-3.88 with 88.98M shares outstanding.
Prana Biotechnology Limited, launched on November 11, 1997, is a development-stage medical biotechnology company. The Company is involved in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Business’s lead product candidates are PBT2 and PBT434. The Business’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Company also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders. PBT2 is a small molecule that reversibly binds and transports copper and zinc within neurons and across synapses..